Genenta Science shares are trading higher after the company announced the Agenzia Italiania del Farmaco approved its Phase 1 trial for metastatic renal cell cancer for its flagship product. Additionally, HC Wainwright & Co reiterated a Buy rating on the stock and maintained its $25 price target.
Portfolio Pulse from Benzinga Newsdesk
Genenta Science shares rose after the Agenzia Italiania del Farmaco approved a Phase 1 trial for its metastatic renal cell cancer treatment. HC Wainwright & Co reiterated a Buy rating with a $25 price target.
October 02, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genenta Science shares increased following the approval of a Phase 1 trial for its cancer treatment by the Italian agency. HC Wainwright & Co reiterated a Buy rating and a $25 price target.
The approval of the Phase 1 trial is a positive regulatory development, likely boosting investor confidence. The reiteration of a Buy rating and a $25 price target by HC Wainwright & Co further supports a positive outlook for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100